Borregaard ASA
Borregaard ASA engages in the development, production, and marketing of specialized biochemicals and biomaterials in Norway, rest of Europe, Asia, the United States, and internationally. It operates in three segments: BioSolutions, BioMaterials, and Fine Chemicals. The company develops, produces, and sells biopolymers and biovanillin for agrochemicals, batteries, industrial binders, and construct… Read more
Borregaard ASA (BRRDF) - Total Liabilities
Latest total liabilities as of September 2025: $397.62 Million USD
Based on the latest financial reports, Borregaard ASA (BRRDF) has total liabilities worth $397.62 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Borregaard ASA - Total Liabilities Trend (2009–2024)
This chart illustrates how Borregaard ASA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Borregaard ASA Competitors by Total Liabilities
The table below lists competitors of Borregaard ASA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ryman Healthcare Limited
PINK:RHCGF
|
USA | $7.95 Billion |
|
Jereissati Participações S.A.
SA:IGTI11
|
Brazil | R$4.79 Billion |
|
Betsson AB (publ)
PINK:BTSNY
|
USA | $433.90 Million |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
|
China | CN¥2.10 Billion |
|
Hakuhodo DY Holdings Inc
OTCGREY:HKUOF
|
USA | $484.89 Billion |
|
Jonjee Hi-tech Industrial and Commercial Holding Co Ltd
SHG:600872
|
China | CN¥2.20 Billion |
|
Betta Pharmaceuticals Co Ltd
SHE:300558
|
China | CN¥3.78 Billion |
|
Innodata Inc
NASDAQ:INOD
|
USA | $55.68 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down Borregaard ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Borregaard ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Borregaard ASA (2009–2024)
The table below shows the annual total liabilities of Borregaard ASA from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.49 Billion | +6.47% |
| 2023-12-31 | $4.22 Billion | +15.04% |
| 2022-12-31 | $3.67 Billion | +28.29% |
| 2021-12-31 | $2.86 Billion | -11.32% |
| 2020-12-31 | $3.23 Billion | -1.68% |
| 2019-12-31 | $3.28 Billion | +24.71% |
| 2018-12-31 | $2.63 Billion | +12.54% |
| 2017-12-31 | $2.34 Billion | +19.36% |
| 2016-12-31 | $1.96 Billion | -7.12% |
| 2015-12-31 | $2.11 Billion | +17.18% |
| 2014-12-31 | $1.80 Billion | +13.29% |
| 2013-12-31 | $1.59 Billion | -12.07% |
| 2012-12-31 | $1.81 Billion | -30.03% |
| 2011-12-31 | $2.58 Billion | +1.33% |
| 2010-12-31 | $2.55 Billion | +22.51% |
| 2009-12-31 | $2.08 Billion | -- |